NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.90
+1.15 (5.82%)
At close: Feb 11, 2026

TPEX:4732 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
180.29224.32160.14228.59249.8306.92
Revenue Growth (YoY)
-19.72%40.08%-29.94%-8.49%-18.61%-0.18%
Cost of Revenue
88.9104.1272.7698.66103.62123.48
Gross Profit
91.39120.287.38129.93146.19183.44
Selling, General & Admin
57.1460.1753.9454.0649.7557.39
Research & Development
78.3372.0730.0149.4869.4668.14
Operating Expenses
135.47132.2283.95103.58119.21125.51
Operating Income
-44.08-12.023.4326.3526.9857.92
Interest Expense
-0.08-0.1-0.05-0.04-0.03-0.06
Interest & Investment Income
7.496.645.963.611.982.34
Currency Exchange Gain (Loss)
-4.581.720.05-0.050.54-0.95
Other Non Operating Income (Expenses)
0.020.10.1-0.161.250.09
EBT Excluding Unusual Items
-41.23-3.659.4929.7130.7259.35
Gain (Loss) on Sale of Investments
--0.440.31-0.08-0.02
Gain (Loss) on Sale of Assets
---0--
Pretax Income
-41.23-3.659.9230.0230.6459.33
Income Tax Expense
6.77-0.07-0.2--0.17-5.98
Earnings From Continuing Operations
-48-3.5810.1230.0230.8165.32
Minority Interest in Earnings
10.994.48----
Net Income
-37.010.910.1230.0230.8165.32
Net Income to Common
-37.010.910.1230.0230.8165.32
Net Income Growth
--91.14%-66.29%-2.54%-52.83%64.54%
Shares Outstanding (Basic)
494949494949
Shares Outstanding (Diluted)
495050494949
Shares Change (YoY)
-1.14%-0.15%0.85%0.30%-0.05%30.58%
EPS (Basic)
-0.750.020.210.610.631.33
EPS (Diluted)
-0.750.020.200.610.621.32
EPS Growth
--90.90%-67.17%-1.75%-53.03%26.05%
Free Cash Flow
-22.58-2.9161.913.8533.7254.61
Free Cash Flow Per Share
-0.46-0.061.240.280.681.11
Dividend Per Share
--0.2000.5000.3000.094
Dividend Growth
---60.00%66.67%218.13%-
Gross Margin
50.69%53.58%54.56%56.84%58.52%59.77%
Operating Margin
-24.45%-5.36%2.14%11.53%10.80%18.87%
Profit Margin
-20.53%0.40%6.32%13.13%12.33%21.28%
Free Cash Flow Margin
-12.53%-1.30%38.65%6.06%13.50%17.79%
EBITDA
-37.61-5.579.8437.1538.0165.54
EBITDA Margin
-20.86%-2.48%6.14%16.25%15.22%21.35%
D&A For EBITDA
6.476.456.410.811.037.62
EBIT
-44.08-12.023.4326.3526.9857.92
EBIT Margin
-24.45%-5.36%2.14%11.53%10.80%18.87%
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.